Novo Nordisk A S annual debt-to-assets ratio
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Debt-to-Assets Ratio Growth & History (NVO)
Novo Nordisk A S's debt-to-assets ratio was 0.26 for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.26 | 0.02 | +9.24% |
| 2024 | 2024-12-31 | 0.24 | 0.13 | +126.05% |
| 2023 | 2023-12-31 | 0.10 | −0.02 | −17.16% |
| 2022 | 2022-12-31 | 0.13 | −0.03 | −20.59% |
| 2021 | 2021-12-31 | 0.16 | 0.06 | +63.45% |
| 2020 | 2020-12-31 | 0.10 | 0.03 | +46.37% |
| 2019 | 2019-12-31 | 0.07 | — | — |
Novo Nordisk A S quarterly debt-to-assets ratio
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.24 | 0.03 | +14.40% |
| Q1 2026 | 2026-03-31 | 0.26 | — | — |
| Q4 2025 | 2025-12-31 | 0.26 | 0.02 | +9.24% |
| Q3 2025 | 2025-09-30 | 0.20 | — | — |
| Q2 2025 | 2025-06-30 | 0.21 | — | — |
| Q4 2024 | 2024-12-31 | 0.24 | 0.13 | +126.05% |
| Q4 2023 | 2023-12-31 | 0.10 | −0.02 | −17.16% |
| Q4 2022 | 2022-12-31 | 0.13 | −0.03 | −20.59% |
| Q4 2021 | 2021-12-31 | 0.16 | 0.06 | +63.45% |
| Q4 2020 | 2020-12-31 | 0.10 | — | — |
Novo Nordisk A S debt-to-assets ratio trends
Over the last five fiscal years, Novo Nordisk A S's debt-to-assets ratio increased from 0.10 to 0.26, a change of 0.16. The latest reported quarter, Q2 2026, shows 0.24.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...